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Abstract.  Membrane-anchored forms of the v-sis on- 
coprotein have been previously described which are 
oriented as type I transmembrane proteins and which 
efficiently induce autocrine transformation.  Several ex- 
amples of naturally occurring membrane-anchored 
growth factors have been identified, but all exhibit a 
type I orientation.  In this work, we wished to con- 
struct and characterize membrane-anchored  growth 
factors with a type II orientation.  These experiments 
were designed to determine whether type II 
membrane-anchored growth factors would in fact ex- 
hibit biological activity. Additionally,  we wished to de- 
termine whether the hydrophobic domain of the E5 
oncoprotein of bovine papilloma virus (BPV) can 
function as a  signal-anchor domain to direct type II 
membrane insertion. 
Type II derivatives of the v-sis oncoprotein were 
constructed,  with the NH2 terminus  intracellular and 
the COOH terminus extracellular,  by substituting the 
NH2 terminal  signal  sequence with the signal-anchor 
domain of a known type II membrane protein.  The 
signal-anchor domains of neuraminidase  (NA), 
asialoglycoprotein receptor (ASGPR) and transferrin 
receptor (TR) all yielded biologically active type II 
derivatives of the v-sis oncoprotein.  Although trans- 
forming all of the type II signal~anchor-sis  proteins 
exhibited a very short half-life.  The short half-life ex- 
hibited by the signal~anchor-sis  constructs suggests 
that,  in some cases, cellular transformation may result 
from the synthesis of growth factors so labile that they 
activate undeteetable autocrine loops. 
The E5 oncoprotein encoded by BPV exhibits amino 
acid sequence similarity with PDGF, activates the 
PDGF B-receptor, and thus resembles a miniature 
membrane-anchored growth factor with a putative type 
II orientation.  The hydrophobic domain of the E5 on- 
coprotein, when substituted in place of the signal se- 
quence of v-sis, was indistinguishable compared with 
the signal-anchor domains of NA, TR, and ASGPR, 
demonstrating  its ability to function as a  signal-anchor 
domain.  NIH 31"3 cells transformed by the sig- 
nal/anchor-sis constructs exhibited morphological 
reversion upon treatment with suramin,  indicating a 
requirement for ligand/receptor interactions in a 
suramin-sensitive compartment,  most likely the cell 
surface. In contrast,  NIH 31"3 cells transformed by the 
E5 oncoprotein did not exhibit morphological rever- 
sion in response to suramin. 
T 
HE v-sis oncoprotein, closely related to the B chain 
of PDGE is synthesized with an NH2-terminal signal 
sequence to direct its translocation  across the mem- 
brane of the RER and into the secretory pathway (Hannink 
and Donoghue, 1984). The v-sis oncoprotein and PDGF are 
usually viewed as examples of secreted growth factors which 
are released from cellular membranes prior to binding  and 
activation  of receptors.  This view remains  fundamentally 
unchanged  by the recent observation that  some forms of 
PDGF contain a basic amino acid sequence leading  to as- 
sociation with the extracellular  matrix  (LaRochelle et al., 
1991; Raines and Ross, 1992), which may restrict their abil- 
ity to diffuse to other cells. 
PDGF belongs to a larger group of growth factors defined, 
in part, by homology among the receptors which they acti- 
vate. The PDGF receptors, including the o~ receptor (Matsui 
et al., 1989) and the B receptor (Yarden et al., 1986), exhibit 
a  "split-kinase "  domain  and  define  a  family  of receptors 
which  includes:  the  stem  cell  factor  (SCF)  ~ receptor or 
c-k# (Qiu et al., 1988); the colony stimulating factor-1 (CSF- 
1. Abbreviations used in this paper: ASGPR, asialoglycoprotein receptor; 
BPV, bovine papilloma  virus; CSILI, colony  stimulating  factor-l;  MLV, 
Moloney murine leukemia virus; NA, neuraminidase; RSV, l~us sarcoma 
virus; SCF, stem cell factor;  TGF*a, transforming growth fi~ctor-~; TR, 
transferfin  receptor;  VSV-G, vesicular stomatitis virus glycoprotein. 
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endothelial growth factor (VEGF) receptor or c-fit (De "Cries 
et al., 1992; Shibuya et al., 1990). Several of the growth fac- 
tors  for  the  "split-kinase"  receptors  are  synthesized  as 
membrane-anchored precursors.  For instance, the growth 
factor  CSF-1  is  synthesized as  two  different membrane- 
anchored  precursors  which  are  released  by  proteolysis 
(Kawasaki et al., 1985; Rettenmier and Roussel, 1988; Wong 
et al., 1987). The ligand of  the c-kit receptor, referred to var- 
iously as SCE mast cell growth factor, or steel factor, is also 
synthesized as a membrane-anchored precursor which un- 
dergoes rapid proteolysis to release mature SCF (Anderson 
et al.,  1990;  Huang et al.,  1990;  Martin et al.,  1990).  In 
these cases, the membrane-anchored precursors are type I 
proteins  in  which the  NH2  terminus  is  topologically ex- 
tracellnlar and the COOH terminus remains within the cyto- 
plasm ("N-out, C-in"). This orientation requires the pres- 
ence  of a  conventional signal  sequence  located near  the 
NH2 terminus of the nascent polypeptide, which is removed 
during translocation across the membrane, coupled with a 
stop-transfer domain or membrane anchor located near the 
COOH terminus. 
Although naturally occurring type I membrane-anchored 
forms of PDGF have not been identified, our laboratory has 
designed and described such constructs previously (Hannink 
and Donoghue,  1986a;  Lee and Donoghue,  1991, 1992), 
using the membrane anchor of the vesicular stomatitis virus 
glycoprotein (VSV-G) to provide for membrane anchoring 
(Rose and Gallione,  1981; Adams and Rose,  1985;  Guan 
et al.,  1985).  These prior studies demonstrated that mem- 
brane-anchored v-sis-G can still induce autocrine transfor- 
mation (Hannink and Donoghne, 1980a), although its ability 
to induce PDGF  receptor autophosphorylation is  signifi- 
cantly reduced (Lee and Donoghue, 1991). 
Petti and DiMaio (1992)  demonstrated that the E5  on- 
coprotein, encoded by bovine papiUomavirus (BPV), can be 
recovered in a complex with activated PDGF/3 receptors. 
The E5 oncoprotein is unusual due to its small size, only 44 
amino acids, with a very hydrophobic NH2-terminal  region 
and a hydrophilic COOH-terminal region (Horwitz et al., 
1988,  1989).  Petti et al. (1991) first noted slight amino acid 
similarity between E5 and PDGF-B. The region of similarity 
includes the last two Cys residues of the minimal transform- 
ing region of v-sis, previously identified by deletion analysis 
(Giese et al., 1987; Sauer and Donoghue, 1988). In addition, 
the tripeptide F~4SL~49V  tS° in a putative receptor activating 
domain of v-sis  (LaRochelle et al.,  1989),  also occurs in 
the E5 oncoprotein (Maher et al.,  1993). 
Previous studies localized the E5 oncoprotein predomi- 
nantly to Golgi membranes and/or the cell surface, with the 
COOH terminus topologically extracellular (Burkhardt et 
al.,  1989).  The presence of an NH2-terminal hydrophobic 
domain, together with a  COOH-terminal hydrophilic do- 
main exhibiting amino acid similarity to PDGF, suggests that 
E5 may function as a "miniature" membrane-anchored ver- 
sion of PDGE  By this model, E5 would exhibit a type II 
orientation,  i.e.,  "N-in,  C-out  S  allowing the  COOH-ter- 
minal hydrophilic domain to be extracellular and available 
for PDGF receptor activation. 
Several type 1I membrane-anchored proteins have been ex- 
tensively  characterized,  including  neuraminidase  (NA) 
(Fields et  al.,  1982;  Sivasubramanian and Nayak,  1987; 
Brown et al., 1988; Nayak and Jabbar, 1989; Kundu et al., 
1991), asialoglycoprotein receptor (ASGPR) (Spiess et al., 
1985; Spiess and Lodish, 1985, 1986), and transferrin recep- 
tor (TR) (Schneider et al., 1984; Zerial et al., 1986; Kundu 
et al.,  1991). These proteins possess a %ignal-anchor" se- 
quence located near the NH2 terminus. The signal-anchor 
sequence provides the dual function of a  signal sequence, 
directing translocation across the membrane of the rough 
ER, as well as a membrane anchor, resulting in the topology 
"N-in, C-out" (Hartmann et al.,  1989;  High et al.,  1991). 
In this study, we sought to determine whether the v-sis on- 
coprotein retains its biological activity when membrane an- 
chored as a type II protein. To accomplish this, the DNA se- 
quence encoding the signal sequence of v-sis was replaced 
with a  sequence encoding the signal-anchor domain of a 
known type II membrane protein. We also wished to exam- 
ine whether the hydrophobic domain of the E5 oncoprotein, 
when substituted in place of the normal signal sequence of 
the v-sis  oncoprotein, could in fact function as a  signal- 
anchor domain. 
Our results indicate that the signal-anchor domains of NA, 
ASGPR and TR, as well as the hydrophobic domain of E5, 
all yield biologically active type II membrane-anchored de- 
rivatives of the v-sis oncoprotein. Although transforming, all 
of the type II signal~anchor-sis derivatives exhibited rapid 
turnover. These results indicate that there is, in principle, no 
reason  to  preclude  the  existence  of naturally  occurring 
membrane-anchored  growth  factors  exhibiting  a  type  II 
orientation. 
Materials and Methods 
Construction of  Plasmids Encoding 
Signal~Anchor-Sis Fusions 
The signal~anchor-sis constructs were derived by substitution of the v-sis 
signal sequence by a heterologous signal-anchor domain. The parental plas- 
mid contained a mutant v-sis gene in which the dibasic proteolytic process- 
ing site Lysll°-Arg m  was previously mutagenized to Asnll°-Ser TM (Haw 
nink and Donoghue, 1986b). Cleavage at this dibasic processing site occurs 
as a late event in the secretory pathway, probably between the trans-Golgi 
compartment and the plasma membrane (Robbins et al.,  1985; Lokeshwar 
et al., 1990; Lee and Donoghue, 1992). This cleavage removes the propep- 
tide sequence and generates the NH2 terminus of the mature PDGE  To 
prevent proteolytic separation of the growth factor domain from the signal- 
anchor domain in the constructs reported here, it was essential to include 
the LysH°--*Asn,  ArglH-'~Ser mutations in all clones. The parental plas- 
mid, designated pRSV-sisNn°S TM, contains the mutant v-sis gene as a Hin- 
dIII-ClaI restriction fragment in a standard plasmid vector under control 
of the Rous sarcoma virus (RSV) promoter. The original pRSV-A~ plasmid 
(obtained from S. Gould and S. Subramani, University of California, San 
Diego, La Jolla, CA) contains the RSV long terminal repeat to drive tran- 
scription of inserted genes followed by the SV-40 poly A  addition site. 
The DNA sequence encoding the signal sequence of v-sis is easily re- 
moved from the parental plasmid pRSV-sisNHOSm as a  HindIII-SstI re- 
striction fragment, where the SstI site corresponds to nucleotide 3828 in 
the sequence of simian sarcoma virus (Devare et al., 1983). Removal of this 
restriction fragment removes the codoas for amino acids 1-59 of wild type 
v-sis protein.  Synthetic restriction fragments encoding heterologous sig- 
nal-anchor domains were prepared using two long complementary oligonu- 
cleotides, designed to produce HindIII and SstI overhangs when annealed. 
The oligonucleotides ranged in length from 83-124 bases, and were pre- 
pared using a DNA synthesizer (381A; Applied Biosystems, Foster City, 
CA) with customized coupling times, reagent delivery times, and column 
configurations to reduce cost and synthesis time. Approximately 25 #g of 
each crude oligonucleotide was applied to a 6% denaturing polyacrylamide 
gel, separated electrophoretically, and the band corresponding to each full- 
length oligonucleotide was excised.  Oligonucleotides were recovered by 
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NHtAc,  10 mM MgAc2), and ethanol precipitation.  Resuspended oligonu- 
cleotides  were  then  ligated  with 0.15 #g  of the vector DNA,  pRSV- 
sis  NH°sHI,  which  was  previously  cleaved  with  HindIH  and  SstI  and 
purified by agarose gel electrophoresis. Recombinant clones were recovered 
by standard techniques and the sequence of the signal-anchor domains en- 
coded by the HindHI-SstI fragments were confirmed by nucleotide sequenc- 
ing. All synthetic oligonucleotides also encoded a XhoI restriction site adja- 
cent to the HindIII site, so that the entirety of the coding region for each 
signal~anchor-sis construct could be swapped into other vectors as either 
XhoI-ClaI or as HindIII-ClaI  restriction fragments. 
As an example, the NA-sis construct required the synthesis of two long 
oligonucleotides, designated D319 and D320, representing the sense strand 
and antisense strand, respectively. The sequence of the sense strand D319 
oligonucleotide  is:  5'  AGCTTCTCGAGACC. AT(3. AAT. CCA.  AAT. 
CAG. AAA. ATA. ATA. ACC. ATT. GGA. TCA. ATC. TGT. CTG. GTA. 
GTC. GGA. CTA. ATT. AGC. CTA. ATA. CTG. CAG. ATA. GGG. AAT. 
ATA. ATC. TCA. ATA. TGG. ATT. AGC. GAG. CT  y. This oligonucleo- 
tide encodes the amino acid sequence MNPNQKIITIGSICLVVGLISLIL- 
QIGNIISIWISEL.  The  amino  acids  encoded  by  oligonucleotides 
D319/D320  represent  amino  acids  1-35 of the  NA  protein  of human 
influenza virus (Fields et al., 1982), including the signal-anchor domain 
defined as amino  acids 7-35 (Fields  et al.,  1982; Sivasubramanian and 
Nayak, 1987; Brown et al., 1988; Nayak and Jabbar,  1989; Kundu et al., 
1991).  It should be noted that the last two amino acids encoded by the 
D319/D320, as well as for the other constructs described below, correspond 
to E  5s and L  59 of wild type v-sis protein encoded at the unique SstI restric- 
tion site. In all constructs,  the sequence surrounding the initiation codon 
was designed to provide for optimal initiation of translation (Kozak, 1986). 
The E5-sis construct was similarly designed using a pair of  oligonucleo- 
tides  designated  D341/D342,  which  encode  the  amino  acid  sequence 
MPNLWFLLFLGLVAAMQLLLLLFLLLFFLVEL.  The first 30 residues 
correspond to amino acids 1-30  of the BPV E5 oncoprotein (DiMaio et al., 
1986). The TR-sis construct was designed using a pair of oligonucleotides 
designated D383/D384.  These oligonucleotides encode the amino acid se- 
quence MKRCSGSICYGTIAVIVFFLIGFMIGYLGYCKEL. Amino acids 
2-32 in this sequence correspond to amino acids 60-90 of the human TR 
protein (Schneider et al., 1984), which includes the signal-anchor domain 
located at amino acids 65-88. The first Met residue encoded by D383/D384 
was added to provide for initiation of translation. The ASGPR-sis construct 
was designed using a pair of  oligonucleotides designated D385/D386. These 
oligonucleotides encode the amino acid sequence MPRLLLLSLGLSLLL- 
LVVVC'VIGSEL. Amino acids 2-24 in this sequence correspond to amino 
acids 39-61 of the human ASGPR HI protein (Spiess et al., 1985), which 
includes the signal-anchor domain located at amino acids 41-59. AS for the 
preceding  construct,  the first Met residue  encoded  by  D385/D386  was 
added to provide for translational  initiation. 
Preparatory  to DNA transfections into NIH 31"3 cells, DNA fragments 
encoding  NA-sis,  E5-sis,  TR-sis,  and  ASGPR-sis  were  subcloned  as 
XhoI-ClaI restriction fragments into the murine leukemia virus (MLV) ex- 
pression vector pDM85, which was derived from the previously described 
retroviral vector pDD102 (Bold and Donoghue,  1985). 
In Vitro Transcription and Translation of 
Signal~Anchor-Sis Constructs 
DNA fragments encoding the signal~anchor-sis were also subcloned from 
the constructs described above into a vector derived from pSP64(polyA) 
(Promega Biotec, Madison, WI), designated pDIM31, which contains an 
SP6 promoter for in vitro transcription. As controls, other sis-related genes 
were subcloned into the SP6-promoter vector, including wild type v-sis and 
v-sis239-G (Hannink and Donoghue,  1986a) which will be designated sim- 
ply as v-sis-G throughout  this  work.  The  5'-capped and polyadenylated 
RNAs were transcribed in vitro as described (Melton,  1987). RNAs were 
analyzed by gel electrophoresis and subjected to in vitro translation in rabbit 
reticulocyte lysates containing 50 #Ci [35S]Cys (1,000 Ci/mmol). Transla- 
tion products were resolved by SDS-PAGE  using 15 % polyacrylamide in the 
separating gel, and detected by autoradiography of the dried gel. 
Cell Culture, Focus Assays, and Transient 
Expression Assays 
NIH 3T3 cells and CV-1 cells were cultured at 37°C in DME containing 
10% calf serum. For focus assays, NIH 3T3 cells were transfected with the 
signal~anchor-sis constructs  described  above, under MLV retroviral pro- 
moter control, together with a replication competent helper  provirus, pZAP 
(Hoffman  et  al.,  1982). DNA  transfections  were  carried  out  using  a 
modified calcium  phosphate  transfection protocol  (Chen and Okayama, 
1987), as described previously (Maher et al., 1993). For some experiments, 
plates of  transfected cells were allowed to overgrow to select for transformed 
cells by splitting cells weekly at a density of 1:6. For transient expression 
assays of  protein expression, transfections into monkey CV-1 cells were car- 
ried out as described above using 12 #g DNA for each signal~anchor-sis 
construct  under RSV promoter control. 
Metabolic Labeling and Immunoprecipitations 
NIH 3T3 or CV-I cells expressing the signal~anchor-sis proteins were used 
as described in the text for immunoprecipitation of radiolabeled protein. 
Before labeling, cells were rinsed and incubated for 15 rain in MEM lacking 
Cys and Met. For pulse-chase  analyses, cells were labeled with 100 #Ci/ml 
each [35S]Cys and [3SS]Met for 30 min, rinsed twice with TBS, and chased 
for 10 min, 30 min, or 2 h in fresh DME. Labeled cells were subsequently 
lysed in 1.0 ml RLPA buffer (10 mM sodium phosphate [pH 7.0], 150 mM 
NaCI, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 1% Aprotinin) and 
clarified lysates were prepared. Immune complexes were formed as previ- 
ously described (Hannink and Donoghue, 1986a), using a rabbit antiserum 
directed against bacterially synthesized v-sis protein generously provided by 
Ray Sweet and Keith Deen (Smith, Kline and French, King of  Prussia, PA). 
Immune complexes were collected using protein A Sepharose (Sigma Im- 
munochemicals, St. Louis, MO). Samples were run on a 12.5% SDS-POly- 
acrylamide gel and processed for fluorography to visualize proteins. 
Indirect Immunofluorescence 
To detect intracellular v-sis fusion proteins, cells were fixed in 3 % parafor- 
maldehyde/PBS for 10 rain, followed by permeabllization in 1% Triton/PBS 
for 5  rain.  Cells  were then incubated  with a  rabbit  antiserum  directed 
against the v-sis protein,  followed by a rhndamine-conjugated goat anti- 
rabbit antibody. To detect cell surface v-sis fusion proteins, cells were fixed 
with paraformaldehyde and incubated with antibodies without permeabili- 
zation,  as described previously (Lee and Donoghue,  1992; Hannink and 
Donoghue,  1986a). 
Results 
Construction of  Signal~Anchor-Sis  Proteins 
The constructs used in this work were prepared by replacing 
the conventional  signal  sequence of v-sis with various sig- 
nal-anchor  domains.  Signal-anchor  domains provide  the 
dual purpose of initiating  protein  translocation  across the 
membrane of the ER, and also provide  for membrane an- 
choring of the protein.  In general,  signal-anchor domains 
provide for a type II membrane orientation,  in which the 
NH2 terminus is located intracellularly  and the COOH ter- 
minus  is  located  extracellularly  ("N-in,  C-out").  As  de- 
scribed in the Materials and Methods, a restriction fragment 
encoding  amino acids  1-59 of the v-sis  protein  was  sub- 
stituted with a synthetic  restriction  fragment  encoding the 
desired  signal-anchor  domain.  The  parental  gene  used, 
designated  v-siss H°s'l also contains a pair of mutations to 
destroy the proteolytic processing site,  LysH°-Arg  m, which 
is used to cleave the propeptide  sequence from the mature 
growth  factor. Otherwise,  the predicted  cleavage  following 
Lysll°-Argllt  would cleave the growth  factor  domain from 
its signal-anchor domain in the signal~anchor-sis constructs. 
The signal-anchor domains used in this study  were de- 
rived from three well-characterized  type II membrane pro- 
teins:  the influenza virus NA protein  (Fields et al.,  1982), 
the human TR protein (Schneider  et al.,  1984), and the hu- 
man ASGPR H1 protein (Spiess et al.,  1985). In addition, 
the hydrophobic domain of the BPV E5 protein (DiMaio et 
al., 1986), was used in these studies to determine if it could 
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Figure 1.  Structure of type II 
membrane-anchored sis pro- 
teins with respect to the mem- 
brane.  The  structure  of the 
signal~anchor-sis  constructs 
with respect to the membrane 
is shown. Also shown are the 
parental  proteins  for  these 
constructs, including the type 
1I proteins NA, TR, ASGPR, 
and  also  the  papillomavirus 
E5  oncoprotein.  The  wild 
type  v-sis protein  and  its 
type  I  membrane-anchored 
derivatives,  v-sis-G  and 
v-sisNn°sm-G, are also shown. 
The extraeellular domain is indicated by a solid triangle, pointing towards the COOH terminus, whose size roughly corresponds to the 
relative size of the extraceUular domain.  The asterisk indicates the site of the Nu°S  m mutation in the dibasic processing site, which 
results in retention of the propeptide sequence. The location of the NH2 terminus (N) and COOH terminus (C) is indicated for each pro- 
tein. Note that many of these proteins exist as dimers or higher order oligomers, which is not shown in this figure. 
also function as a signal-anchor domain. The resulting con- 
structs were designated NA-sis, TR-sis, ASGPR-sis, and E5- 
sis,  and were prepared under MLV promoter control and 
RSV promoter control. 
The general structure of the signal~anchor-sis constructs 
with respect to the membrane is shown diagrammatically in 
Fig. 1, together with the parent proteins. In previous studies, 
we also made use of a type I membrane-anchored derivative 
of v-sis, designated v-sis-G, in which the transmembrane do- 
main of VSV-G was appended near the COOH terminus of 
the PDGF-related domain (Hannink and Donoghue, 1986a; 
Lee and Donoghue, 1992). 
The Signal~Anchor-Sis Constructs Transform 
NIH 3T3 Cells 
The three different signal~anchor-sis constructs described 
here, NA-sis, TR-sis, and ASGPR-sis, all transformed cells 
with  efficiencies similar to the type I  construct,  v-sis-G, 
ranging from 25--46% compared with wild type v-sis (see 
Table I, and also Fig. 6). Importantly, the construct E5-sis 
also transformed NIH 3T3 cells with an efficiency compara- 
ble to the signal~anchor-sis constructs. The ability of E5-sis 
to induce morphological transformation demonstrates that 
the hydrophobic domain of the BPV E5 oncoprotein can in- 
deed  initiate  translocation  of the  PDGF-related  domain 
across the membrane. 
Table L  Transformation  Efliciencies  of 
Signal~Anchor-sis  Constructs 
Construct  Relative transformation* 
v-sis  100% 
E5  83% 
mock  < 1% 
E5-sis  32% 
NA-sis  30% 
TR-sis  46% 
ASGPR-sis  25 % 
v-sis-G  26% 
* Transformation  relative to that produced by v-sis (set to 100%). 
In earlier work (Lee and Donoghue, 1992), we observed 
that the foci of NIH 3T3 cells transformed by type I v-sis-G 
are smaller and "tighter" than the foci generated by wild type 
v-sis,  presumably due to the  inability  of the  membrane- 
anchored growth factor to diffuse in the medium. Similarly, 
the foci generated by the four novel constructs described 
here, NA-sis, TR-sis, ASGPR-sis, and E5-sis,  all resembled 
v-sis-G in this respect, producing foci that were in general 
about one third the size of those produced by wild type v-sis. 
The Signal~Anchor-Sis Proteins Exhibit 
Rapid Turnover 
We next attempted to detect the various signal~anchor-sis 
proteins by immunoprecipitation and SDS-PAGE analysis of 
radiolabeled cell lysates. In preliminary experiments, under 
conditions  readily  allowing  detection of control  proteins 
such as wild type v-sis or v-sis-G,  we occasionally detected 
faint bands of radiolabeled proteins corresponding to the sig- 
nal/anchor-sis  proteins (data  not shown).  To demonstrate 
that the constructs encoded the expected proteins, we turned 
to an in vitro transcription/translation system. Results of a 
typical experiment are presented in Fig. 2, which shows pro- 
teins  translated  in  vitro,  using  rabbit  reticulocyte lysate, 
from the constructs E5-sis (Fig. 2, lane/) and NA-sis (lane 
2), in comparison with the control proteins wild type v-sis 
(lane 3) and v-sis-G (lane 4). In the experiment shown, the 
in vitro translations were subjected to immunoprecipitation 
with an antiserum against the v-sis protein before SDS-PAGE 
analysis. However, essentially identical bands were observed 
if the  translations  were  analyzed by  SDS-PAGE directly 
without  immunoprecipitation  (data  not  shown).  The  ob- 
served molecular weights were in general agreement with the 
predicted molecular weights given that the signal sequence 
would not be cleaved from the wild type v-sis and v-sis-G 
proteins under the conditions used for in vitro translation, 
nor  would  any  of these  polypeptides  undergo  N-linked 
oligosaccharide addition. Note that in Fig. 2 (lanes 3 and 4) 
the lower band of the observed doublet is due to initiation 
during in vitro translation at a second AUG codon in the sig- 
nal sequence of v-sis,  shown previously to result in a func- 
tional protein (Hannink and Donoghue,  1984). 
This experiment demonstrates that in rabbit reticulocyte 
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of sis-related proteins. RNAs 
transcribed  in  vitro  using 
SP6-promoter  constructs 
were  translated  using  rabbit 
reticulocyte  lysate,  labeled 
with [3sS]Cys, and the result- 
ing  protein  products  were 
resolved by 15%  SDS-PAGE 
and detected by fluorography 
of the dried gel. In the experi- 
ment shown, translation prod- 
ucts were immunoprecipitated 
prior to  SDS-PAGE using  a 
polyclonal  antibody  directed 
against v-sis. Lane 1, E5-sis; 
lane 2,  NA-sis;  lane 3, wild 
type v-sis; and lane 4, v-sis-G. 
Arrows  indicate  primary 
translation  products  which 
correspond  to predicted mo- 
lecular weights for the differ- 
ent  constructs.  Note  that  in 
lanes 3 and 4 the lower band 
of the observed doublet is due 
to  the  usage  of an  internal 
AUG initiation codon  in the 
v-sis  gene  during  in  vitro 
translation.  Autoradiogram 
was exposed for 2 h at -70°C. 
lysate,  the  signal~anchor-sis  proteins  were  translated  as 
efficiently as the control proteins v-sis  and v-sis-G.  Fig.  2 
also demonstrates that the recovery of the signal~anchor-sis 
proteins after immunoprecipitation was comparable to the 
recovery of the control proteins v-sis and v-sis-G. This indi- 
cates that the presence of the signal-anchor domain in the 
signal~anchor-sis  proteins did not interfere with the ability 
of the antiserum to immunoprecipitate the protein. 
Unfortunately, these results provided no explanation for 
the  inability  to  detect  significant  expression  of the  sig- 
nal/anchor-sis  proteins in either transformed cells or tran- 
siently expressing cells.  Suspecting that the signal/anchor- 
sis proteins might be quite unstable, a pulse-chase analysis 
was undertaken to determine the rate of turnover of the sig- 
nal/anchor-sis proteins. A short labeling period (30 min) was 
used to incorporate [3~S]Cys and psS]Met, followed by var- 
ious chase times during which cells were incubated in non- 
radioactive  media.  Using  these  conditions,  radioactively 
labeled proteins could be detected following immunoprecipi- 
tation  and  SDS-PAGE,  as  shown  in  Fig.  3,  and  which 
comigrated with the protein products obtained by in vitro 
transcription/translation (data not shown). Data for the E5- 
sis (Fig. 3, lanes 5-8) and for the Na-sis (Fig. 3, lanes 9--12) 
constructs are shown.  Quantitation of the bands shown in 
Fig. 3 revealed a half-life of •19  min (±5 min) for the E5-sis 
and NA-sis constructs, compared with the much longer half- 
life of *  2  h  for the control protein v-sis-G  (Fig.  3,  lanes 
13-16;  and previously determined by Lee and  Donoghue, 
Figure 3. Pulse-chase analysis 
of E5-s/s and NA-sis proteins 
in  comparison  with  v-sis-G. 
Ceils expressing different sis- 
related proteins were labeled 
with  [3sS]Cys and  [~sS]Met 
for 30 min,  and then shifted 
into  fresh  DME  for  chase 
periods of 10 min, 30 rain, or 
2  h.  Lanes  1-4,  mock- 
transfected  cells;  lanes  5-8, 
cells expressing E5-sis;  lanes 
9-12, cells expressing NA-sis; 
lanes  13-16,  cells expressing 
v-sis-G.  Proteins were recov- 
ered by immunoprecipitation, 
separated  by  15%  SDS- 
PAGE,  and  detected  by 
fluorography. Exposure  time 
was 11 d at  -70  °. 
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and ASGPR-sis were similarly unstable, comparable to the 
E5-sis and NA-sis proteins (data not shown). These results 
indicate that the signal~anchor-sis  proteins turn over very 
rapidly and explained the earlier difficulty in their detection. 
We wished to confirm that the signal~anchor-sis  proteins 
were not being detectably released from the cell surface. 
Therefore,  we  immunoprecipitated  radiolabeled  proteins 
released into the media in comparison with proteins recov- 
ered from lysates of  the same cells. Although this experiment 
was  conducted using  a  variety of conditions,  the highest 
recovery of radiolabeled protein was obtained using RSV- 
promoter constructs  in  transient  assays  in  CV-1 monkey 
cells. In these experiments, no secreted protein could be de- 
tected for any of the signal~anchor-sis  proteins, nor for the 
type  I  membrane-anchored  derivative,  v-sis-G  (data  not 
shown), although secreted v-sis protein was easily detected 
in the media consistent with previous reports (Robbins et al., 
1985;  LaRochelle et al.,  1991).  This experiment was per- 
formed near the limit of detection for the signal~anchor-sis 
proteins, due to their rapid turnover. Since the amount of sig- 
nal/anchor-sis  proteins  detected  in  the  lysates  never  ex- 
ceeded 5 % of  the amount of v-sis protein, it would have been 
difficult to detect proteolytic cleavage and/or secretion of a 
small fraction of the signal~anchor-sis  proteins. Despite this 
reservation,  we  conclude that  in  contrast to  the  efficient 
cleavage and secretion of v-sis protein, little or no detectable 
secretion occurs for the signal~anchor-sis  proteins. 
Immunofluorescence Localization of 
Signal~Anchor-Sis Proteins 
Indirect immunofluorescence was used in an effort to deter- 
mine  the  subcellular  localization  of  the  various  signal/ 
anchor-sis proteins. We first examined NIH 3T3 cells per- 
meabilized by treatment with 1% Triton to allow detection 
of intracellular proteins. Proteins were detected using an an- 
tiserum against the v-sis protein, followed by a  secondary 
rhodamine-conjugated goat anti-rabbit  antiserum.  Fig.  4 
demonstrates that intracellular protein was readily detected 
for two control proteins, wild type v-sis (Fig. 4, B) and v-sis- 
G  (C) protein. Similarly, the signal~anchor-sis  proteins all 
demonstrated reticular ER/Golgi staining, as shown for E5- 
sis (Fig. 4, D and E) and NA-sis (F). The constructs TR-sis 
and ASGPR-sis  also exhibited similar staining patterns in 
permeabilized cells (data not shown). 
We previously demonstrated cell surface expression of the 
type I derivatives, v-sis-G,  and v-sisNtl°sm-G,  whereas cell 
surface  staining  is  essentially undetectable  for wild type 
v-sis (Hannink and Donoghue, 1986a). We therefore exam- 
Figure 4. Intracellular localization of sis-related proteins by immunofluorescence  microscopy. An antibody directed against the v-sis protein 
was used to detect the intracellular localization of sis-related proteins in transformed NIH 3"1"3  cells by indirect immunofluorescence. (.4) 
Control NIH 31"3 cells; (B) wild type v-sis; (C) v-sis-G; (D and E) E5-sis; and (F) NA-sis. Except for the control cells, all the other cells 
exhibit reticular ER/Golgi staining characteristic of sis-related proteins. 
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cell  surface  localization  of 
sis-related  proteins  by  im- 
munofluorescence  micros- 
copy. Indirect immunofluores- 
cence  with  an  antibody 
against v-sis was used to de- 
tect protein expression in ei- 
ther cells permeabilized with 
1% Triton to detect intracel- 
lular proteins,  or nonperme- 
abilized  cells  to  detect  cell 
surface  expression.  (,4) 
IntraceUular  expression  of 
v-sisN"°sH~-G; (B) cell surface 
expression  of  v-sisNtI°Sm-G; 
(C) intracellular expression of 
ASGPR-sis; (D) cell surface 
expression of ASGPR-sis. (E) 
intraceUular expression of  E5- 
sis;  (F) cell  surface expres- 
sion of E5-sis. 
ined nonpermeabitized NIH 3T3 cells expressing each of the 
signal~anchor-sis constructs for cell surface staining using an 
antiserum against v-sis (Fig. 5). As a control, the staining 
of cells expressing v-SiSNII°s1't-G  is shown for both permea- 
bilized cells (Fig. 5 A) and nonpermeabilized cells (B). In 
general, cells expressing the signai/anchor-sis  proteins ex- 
hibited much lighter staining than these control cells. How- 
ever, in populations of acutely infected NIH 3"1"3  cells, it was 
possible to identify cells exhibiting similar staining patterns. 
For example, Fig. 5  (C and D) show intracellular and cell 
surface staining for ASGPR-sis, and E and F show intracel- 
lular and cell surface staining for E5-sis. 
Suramin Reverts Transformation by the 
Signal~Anchor-Sis Proteins, but Not by BPV E5 
Transformation by PDGF-related growth factors has been 
shown previously to be sensitive to suramin,  a polysulfo- 
nated naphthylurea derivative, which results in morphologi- 
cal reversion to a "flat" phenotype (Fleming et al., 1989; Lee 
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of cells  from  transformation 
assay. For each construct, the 
left panel  shows ceils in the 
absence of suramin (A, C, E, 
G, L K, M, and O), while the 
fight panel shows cells in the 
presence of 100 ILM suramin 
(B, D, F, H, J, L, N, and P). 
(A  and  B)  Mock-transfected 
NIH  3"1"3 cells.  (C  and  D) 
Cells  transformed  by  wild 
type  v-sis.  (E and  F) Cells 
transformed  by  v-sis-G.  (G 
and H) Cells transformed by 
wild type E5. (/and J) Cells 
transformed by E5-sis. (K and 
L) Cells transformed by NA- 
sis.  (M and N)  Cells  trans- 
formed by ASGPR-sis. (0 and 
P)  Cells  transformed  by 
TR-sis. 
and Donoghue,  1992). To the extent that cells transformed 
by the signal~anchor-sis constructs might exhibit morpholog- 
ical reversion upon suramin treatment, this would provide 
clear evidence that the PDGF-related domain was translo- 
cated across the membrane and transported to a  suramin- 
accessible compartment of  the cell, such as the plasma mem- 
brane. As shown in Fig. 6, cells transformed by each of the 
signal~anchor-sis constructs were examined in the absence or 
presence of suramin  (overnight at  100 t~M).  Cells  trans- 
formed by all of  these constructs, including E5-sis, exhibited 
morphological reversion as  did cells transformed by wild 
type v-sis. These results clearly demonstrate that the hydro- 
phobic domain of E5 can target the PDGF-related domain 
of the E5-sis construct to the same subcellular compartment 
as  achieved  by  the  well-characterized  signal-anchor  do- 
mains of NA, TR, and ASGPR. 
In contrast to the signal~anchor-sis constructs, cells trans- 
formed by expression of the native BPV E5 oncoprotein did 
not exhibit morphological reversion in response to suramin. 
The E5 oncoprotein has previously been localized to intra- 
cellular membranes of the cell, and the suramin insensitivity 
of this transforming interaction might suggest a Golgi local- 
ization of the transforming interaction between the E5 on- 
coprotein and  PDGF receptors.  This would be consistent 
with a recently proposed model for PDGF receptor activa- 
tion by E5 occurring in the Golgi (Petti and DiMaio, 1992). 
Discussion 
Sis Is Biologically Active As a 1),pe II 
Membrane-anchored Protein 
Previously, we demonstrated that v-sis can be tethered to the 
membrane as a type I protein using the membrane anchor 
and  cytoplasmic tail of VSV-G  (Hannink and  Donoghue, 
1986a;  Lee and Donoghue,  1992).  In the study presented 
here, we have extended our earlier results to describe biolog- 
ically active derivatives which are membrane anchored as 
type II proteins. 
Membrane insertion of type I proteins, which display an 
"N-out, C-in" orientation, has been extensively character- 
ized (Walter and Lingappa, 1986; Rapoport and Wiedmann, 
1985).  Translocation across the membrane for type I pro- 
teins is initiated by a cleavable signal sequence, and mem- 
brane anchoring is provided by a  separate domain located 
nearer to the COOH terminus. In contrast, type II proteins 
insert into the membrane using a signal-anchor domain that 
initiates translocation across the membrane and also serves 
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1986; Lipp and Dobberstein,  1988). Despite the difference 
in the final orientation between type I and II proteins, the ba- 
sic mechanism of insertion may be quite similar as both re- 
quire signal recognition particle (SRP) for membrane inser- 
tion (High et al., 1991). Previous comparisons of  types I and 
II transmembrane domains suggest that the one fundamental 
difference may be the relative charge distribution within 15 
residues flanking the transmembrane segment (Hartmann et 
al.,  1989). In general, the extracellular  segment exhibits a 
greater net negative charge  compared  to the  intracellular 
segment. 
The proteins NA, TR, and ASGPR represent classic type 
II proteins which have been well characterized. For example, 
the signal-anchor domain of NA has been extensively muta- 
genized to define a minimal region comprising the redundant 
functions  of both signal  sequence  and membrane  anchor 
(Brown et al., 1988; Nayak and Jabbar,  1989). The TR sig- 
nal-anchor domain has been used to direct the membrane in- 
sertion of  heterologous proteins such as dihydrofolate reduc- 
tase and ot-globin (Zerial et al., 1986). A recent study also 
demonstrated interchangeability  of the  NA  and  TR  sig- 
nal-anchor domains, with the resulting chimeric molecules 
transported  to the cell surface (Kundu et al.,  1991). 
The  results  presented  here  demonstrate  that  the  sig- 
nal-anchor domains  of the type II proteins  NA,  TR and 
ASGPR can all function to direct membrane insertion of a 
biologically active derivative of the v-sis oncoprotein. 
The Hydrophobic Domain of the E50ncoprotein 
Functions as a Signal Anchor 
Previous  studies have demonstrated  that the BPV E5 on- 
coprotein,  only 44 amino acids,  can be divided  into two 
general domains.  The NH2-terminal two-thirds is very hy- 
drophobic  and may represent  a  membrane-spanning  seg- 
ment, whereas the COOH-terminal  domain is hydrophilic. 
Previous studies have yielded conflicting results concerning 
the subeellular  localization  of the E5 protein.  Studies  in 
which  synthetic  E5-derived  peptides  were  microinjected 
directly into cells suggested that its site of action might be 
cytoplasmic or even nuclear (Rawls et al., 1989; Green and 
Loewenstein,  1988). Other  studies,  using  indirect  im- 
munofluorescence, identified E5 in cellular membrane frac- 
tions presumably  derived from the Golgi or plasma mem- 
brane.  E5 has been identified in a complex with the 16-kD 
subunit of  the vacuolar ATPase (Goldstein et al., 1991, 1992) 
and more recently with PDGF #-receptor (Petti and DiMaio, 
1992), suggesting a membrane localization for E5. Petti and 
DiMaio (1991) first observed amino acid sequence similarity 
between  the hydrophilic domain of E5 and PDGE  Since 
PDGF acts from the extracellular  side of the membrane to 
activate PDGF receptors, these observations suggest that the 
hydrophilic (COOH-terminal)  domain of E5 would also be 
located extracellularly. This inferred orientation as a type II 
membrane protein  ("N-in,  C-out") for the E5 oncoprotein 
would place a net positive charge on the inner face and a net 
negative charge on the outside of the membrane, consistent 
with the other transmembrane  segments (Hartmann et al., 
1989). 
The results presented here clearly demonstrate that the E5 
oncoprotein  possesses  a functional signal-anchor domain, 
similar to type II proteins  such as NA, TR, and ASGPR. 
Three separate results support this conclusion. First, the E5- 
sis construct  results  in cellular  transformation,  indicating 
that the PDGF-related domain has been translocated across 
the membrane. Second, the ability of  suramin to revert trans- 
formation  by E5-sis demonstrates  functional  interactions 
with PDGF receptors  at the cell  surface,  consistent  with 
prior studies localizing the site of ligand/receptor  interac- 
tions for PDGF (Hannink and Donoghue,  1988; Fleming et 
al.,  1989; Lee and Donoghue,  1992). Third, the ability to 
detect  cell  surface  localization  of E5-sis by  indirect  im- 
munofluorescence directly confirms the ability of the E5 hy- 
drophobic domain to provide for membrane anchoring. 
Comparison with Other Membrane-anchored 
Growth Factors 
PDGF occurs naturally as three different dimeric forms: AA 
and BB homodimers, and AB heterodimers. Although none 
of  these forms contains any transmembrane domains, recent 
work suggests a stable association with the extracellular ma- 
trix due to a basic amino acid sequence within the COOH- 
terminal domain (LaRochelle et al., 1990, 1991; Raines and 
Ross, 1992). Thus, although not a classical transmembrane 
protein,  PDGF-BB may exert some autocrine or paracrine 
effects by virtue of remaining associated with the extracellu- 
lar matrix. In contrast, the v-sis-G and the signal~anchor-sis 
proteins are clearly membrane  anchored,  as is the E5 on- 
coprotein which may be viewed as a miniature membrane- 
anchored analog of PDGE 
Table II also presents other growth factors which are mem- 
brane anchored,  all with a type I orientation except for the 
E5 oncoprotein. For most of these, differences in biological 
activity as a result of  membrane anchoring have not yet been 
demonstrated.  However, recent studies have examined the 
mitogenic  properties  of the membrane-anchored  form of 
SCF in comparison with an exclusively secreted form. Al- 
though both forms are active in proliferation  assays using 
mast cells, only the membrane-anchored form of  SCF stimu- 
lates the survival of  primordial germ cells (Dolci et al., 1991; 
Godin et al., 1991). Transforming growth factor-c~ (TGF-t~) 
provides another  interesting case,  and studies have shown 
that an "obligate"  membrane-anchored form of  TGF-ct stimu- 
lates EGF receptors of heterologous cells in a paracrine  in- 
teraction  (Brachmann et al.,  1989; Wong et al.,  1989). 
Reduced Receptor Autophosphorylation by 
Membrane-anchored Growth Factors 
Previously, we demonstrated that the type I protein v-sis-G, 
although transforming in NIH 3T3 cells, induces little or no 
detectable tyrosine phosphorylation of  PDGF receptors (I.e,e 
and Donoghue,  1992). Similarly, previous studies of mem- 
brane-anchored  proTGF-o~ demonstrated  a 50-100-fold re- 
duction,  compared with secreted TGF-tx, in stimulation of 
EGF receptor tyrosine phosphorylation  (Brachmann et al., 
1989). We therefore wished to examine the signal~anchor-sis 
constructs described here for their ability to induce tyrosine 
phosphorylation of  PDGF/3-receptors. We were consistently 
unable to detect any phosphorylation of PDGF receptors in 
cells expressing the signal~anchor-sis proteins, either in sta- 
bly transformed  cell  lines  or transiently  expressing  cells 
(data not shown). This observation allows for two possible 
interpretations.  First, the signal~anchor-sis proteins may in- 
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no  secreted; some isoforms extracellular matrix associated 
yes  artificial construct; VSV-G membrane anchor 
yes  44 amino acid bovine papillomavirus oncoprotein; 
homology with PDGF 
yes  alternative splicing yields two transmembrane forms, 
released by proteolysis 
yes  proteolytic release from transmembrane precursor 
yes  proteolytic release from transmembrane precursor 
yes  proteolytic release from enormous transmembrane precursor 
yes  vaccinia virus growth factor; homolog of EGF 
(LaRochelle,  1990,  1991;  Raines and Ross,  1992) 
(Hannink and Donoghue,  1986a;  Lee and Donoghue,  1992) 
(Petti et al.,  1991) 
(Kawasaki et al.,  1985;  Rettenmier and Roussel,  1988; 
Wong et al.,  1987) 
(Anderson et al.,  1990;  Huang et al.,  1990; 
Martin et al.,  1990) 
(Brachmann et al.,  1989;  Wong et al.,  1989) 
(Gray et al.,  1983;  Scott et al.,  1983) 
(Stroobant et al.,  1985) 
duce receptor autophosphorylation which  is  undetectable 
due to the small number of molecules involved. Second, the 
signal~anchor-sis proteins,  like  v-sis-G and  membrane- 
anchored pro-TGF-ot, may be deficient in their ability to in- 
duce receptor autophosphorylation. At the present time, we 
are  unable  to  distinguish  between  these  two  alternative 
views. 
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Why Are the Signal~Anchor-Sis Proteins So Unstable? 
The short half-life exhibited by the signal~anchor-sis pro- 
teins might conceivably be dependent upon interaction with 
PDGF receptors. To examine this possibility, transient ex- 
pression assays were conducted using canine epithelial cell 
lines either lacking PDGF receptors or specifically express- 
ing the PDGF E-receptor (Kazlauskas and Cooper,  1989). 
These experiments demonstrated that the signal~anchor-sis 
proteins were equally short-lived in both cell lines (data not 
shown),  indicating that the presence or absence of PDGF 
receptors did not influence their turnover. The reasons for 
the intrinsic instability of the signal~anchor-sis  proteins will 
require further investigation. 
The instability of the signal~anchor-sis  proteins made their 
detection and characterization in this study quite difficult. 
Although no examples of naturally occurring type II mem- 
brane-anchored growth factors have been reported, there is 
no reason a priori that type II growth factors should not exist 
in nature. It is impossible to predict whether the instability 
of the signal~anchor-sis  proteins will represent a general fea- 
ture of type II growth factors. 
Unstable Growth Factors May Result in "Ephemeral" 
Autocrine Loops 
The short half-life of the signal~anchor-sis constructs de- 
serves one further comment, as it seems surprising that such 
labile growth factors should result in autocrine transforma- 
tion. This suggests that in some cases cellular transformation 
may result from the synthesis of growth factors which are so 
transitory as to be undetectable, and that some transformed 
cells may exhibit autocrine loops of such an ephemeral na- 
ture as to preclude their identification. 
We wish to thank Ray Sweet and Keith Deen for their gift of antiserum 
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